These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 3320205)
1. Removal of Langerhans cells from human epidermal cell suspensions by immunomagnetic particles. Nilsson H; Johansson C; Scheynius A J Immunol Methods; 1987 Dec; 105(2):165-9. PubMed ID: 3320205 [TBL] [Abstract][Full Text] [Related]
2. A method for the rapid isolation of human epidermal Langerhans cells using immunomagnetic microspheres. Hanau D; Schmitt DA; Fabre M; Cazenave JP J Invest Dermatol; 1988 Sep; 91(3):274-9. PubMed ID: 3411146 [TBL] [Abstract][Full Text] [Related]
3. T-lymphocyte-activating properties of epidermal antigen-presenting cells from normal and psoriatic skin: evidence that psoriatic epidermal antigen-presenting cells resemble cultured normal Langerhans cells. Demidem A; Taylor JR; Grammer SF; Streilein JW J Invest Dermatol; 1991 Sep; 97(3):454-60. PubMed ID: 1875046 [TBL] [Abstract][Full Text] [Related]
4. The mixed epidermal cell-lymphocyte reaction. II. Epidermal Langerhans cells are responsible for the enhanced allogeneic lymphocyte-stimulating capacity of normal human epidermal cell suspensions. Sontheimer RD J Invest Dermatol; 1985 Jul; 85(1 Suppl):21s-26s. PubMed ID: 3159806 [TBL] [Abstract][Full Text] [Related]
5. Purification of functional active epidermal Langerhans cells: a simple and efficient new technique. Morris J; Alaibac M; Jia MH; Chu T J Invest Dermatol; 1992 Aug; 99(2):237-40. PubMed ID: 1629635 [TBL] [Abstract][Full Text] [Related]
6. Enrichment of unlabeled human Langerhans cells from epidermal cell suspensions by discontinuous density gradient centrifugation. Teunissen MB; Wormmeester J; Kapsenberg ML; Bos JD J Invest Dermatol; 1988 Oct; 91(4):358-62. PubMed ID: 2844911 [TBL] [Abstract][Full Text] [Related]
14. In vivo treatment with anti-I-A antibodies: differential effects on Ia antigens and antigen-presenting cell function of spleen cells and epidermal Langerhans cells. Aberer W; Kruisbeek AM; Shimada S; Katz SI J Immunol; 1986 Feb; 136(3):830-6. PubMed ID: 3455705 [TBL] [Abstract][Full Text] [Related]
15. Neutrophils, differentiated macrophages, and monocyte/macrophage antigen presenting cells infiltrate murine epidermis after UV injury. Cooper KD; Duraiswamy N; Hammerberg C; Allen E; Kimbrough-Green C; Dillon W; Thomas D J Invest Dermatol; 1993 Aug; 101(2):155-63. PubMed ID: 8393901 [TBL] [Abstract][Full Text] [Related]
16. Flow cytometrically-sorted residual HLA-DR+T6+ Langerhans cells in topical steroid-treated human skin express normal amounts of HLA-DR and CD1a/T6 antigens and exhibit normal alloantigen-presenting capacity. Ashworth J; Kahan MC; Breathnach SM J Invest Dermatol; 1989 Feb; 92(2):258-62. PubMed ID: 2783952 [TBL] [Abstract][Full Text] [Related]
19. In vivo ultraviolet-exposed human epidermal cells activate T suppressor cell pathways that involve CD4+CD45RA+ suppressor-inducer T cells. Baadsgaard O; Salvo B; Mannie A; Dass B; Fox DA; Cooper KD J Immunol; 1990 Nov; 145(9):2854-61. PubMed ID: 1976706 [TBL] [Abstract][Full Text] [Related]
20. Retinoic acid upregulates human Langerhans cell antigen presentation and surface expression of HLA-DR and CD11c, a beta 2 integrin critically involved in T-cell activation. Meunier L; Bohjanen K; Voorhees JJ; Cooper KD J Invest Dermatol; 1994 Dec; 103(6):775-9. PubMed ID: 7798614 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]